Introduction: Toll-like receptor 5 (TLR5), the pattern recognition receptor for bacterial flagellin, plays an important role in innate immunity. We recently identified TLR4, the receptor for lipopolysaccharide, as a susceptibility gene for Crohn's disease (CD) (Inflamm Bowel Dis 2005; 11:645 52) . We therefore investigated the role of TLR5 variants on susceptibility and phenotype of inflammatory bowel disease (IBD). Aims and Methods: Genomic DNA from 594 Caucasian individuals including 190 patients with CD, 139 patients with ulcerative colitis (UC), and 265 healthy unrelated controls) was genotyped for the SNPs rs5744168=p.Arg392X, rs2072493=p.Asn592Ser, and rs5744174=p.Phe616Leu in the TLR5 gene. Results: None of the three TLR5 SNPs investigated was found to be associated with CD or UC susceptibility. The detailed results of the genotyping analysis are shown in Table 1 . Conclusion: Despite its important role as flagellin receptor, this study does not support a role for TLR5 in the genetic susceptibility of IBD. However, larger replication studies are needed to confirm this finding. Given that TLR5 may play a role in particular disease subtypes, an ongoing genotype-phenotype analysis of our institution is investigating the potential effect of TLR5 variants on the IBD phenotype.
P239
Pregnancy outcomes in women exposed to adalimumab:
Introduction: Adalimumab is a fully human, anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and juvenile idiopathic arthritis in the United States and elsewhere.
Methods: This report describes preliminary outcomes from an ongoing study of the safety of adalimumab in pregnant patients conducted by the Organization of Teratology Information Specialists (OTIS). Through a prospective cohort design, women with RA treated with adalimumab during the first trimester of pregnancy were followed throughout pregnancy and for 1-year postpartum. Pregnancy outcomes were compared with those from a disease-matched group of pregnant women with RA without adalimumab treatment during pregnancy, and a healthy (i.e., non-diseased) group of women who neither had RA nor had been treated with adalimumab. In addition, OTIS investigators collected information on adalimumab-exposed pregnancies that did not meet the cohort criteria, but were followed as a case series. The case-series pregnancies are presented separately as they have no comparison group. They include patients treated for diseases other than RA, such as Crohn's disease, and retrospectively reported outcomes. Results: As of October 31, 2008, pregnancy outcomes were available for 138 women in the cohort study (Tables 1 and  2 ). Approximately 44% of women in the adalimumab-exposed cohort had discontinued the medication in their first trimester, while 41% of subjects had continued the medication through their third trimesters (Table 3) . Two major structural defects (6.9%) had been reported among infants born to 33 women with adalimumab exposure during their first trimesters, for whom pregnancy outcomes were known: 1 undescended testicle and 1 microcephaly. For 52 pregnancies in the disease-matched comparison group with known pregnancy outcome, 1 fetus (1.9%) was diagnosed with chromosomal abnormalities. Two major structural defects (4.4%) were reported in 46 pregnancies with known outcomes in the healthy comparison group. Of the 101 known outcomes in the case-series group, 40 subjects had a diagnosis of Crohn's disease. Eight (7.9%) major anomalies had been reported among children born to 101 women in the case-series group, including those retrospectively enrolled (data not included in the table): 3 chromosomal anomalies, 1 spina bifida with hydrocephalus, 1 bicuspid aortic valve and agenesis of the corpus callosum, 1 ventricular septal defect, 1 congenital hip dysplasia with inguinal hernia, and 1 congenital hypothyroidism. Conclusion: Based on these preliminary data, no concerns have been raised regarding increased risks for adverse pregnancy outcomes associated with early pregnancy exposure to adalimumab in the treatment of RA. Firm conclusions await accumulation of sufficient sample size in this prospective cohort study.
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